JOSÉ ÁNGEL
HERNÁNDEZ RIVAS
Profesor asociado de Ciencias de la Salud
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (21)
2024
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease
Annals of Hematology
-
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
The Lancet Haematology, Vol. 11, Núm. 9, pp. e659-e670
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
-
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Blood, Vol. 139, Núm. 10, pp. 1588-1592
-
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
2021
-
Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: A randomized phase 3 study
Blood Advances, Vol. 5, Núm. 17, pp. 3354-3361
-
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group
Cancer Medicine, Vol. 10, Núm. 4, pp. 1314-1326
2020
-
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
Experimental Hematology and Oncology
-
Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)
British Journal of Haematology, Vol. 190, Núm. 6, pp. 854-863
2017
-
CT-P10 versus reference rituximab in combination with CVP in advanced-stage follicular lymphoma: Phase 3, double-blind, randomized trial
Annals of Oncology, Vol. 28, pp. x94
-
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial
The Lancet Haematology, Vol. 4, Núm. 8, pp. e362-e373
-
Linfomas con reordenamiento de MYC distintos del linfoma de Burkitt: comparación entre R-CHOP y la inmunoquimioterapia tipo Burkitt
Medicina Clinica, Vol. 149, Núm. 8, pp. 339-342
2015
-
Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: The GAH Scale
Journal of Geriatric Oncology, Vol. 6, Núm. 5, pp. 353-361
2013
2012
-
Chronic lymphocytic leukaemia with 17p deletion: A retrospective analysis of prognostic factors and therapy results
British Journal of Haematology, Vol. 157, Núm. 1, pp. 67-74
2002
-
Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease
AIDS, Vol. 16, Núm. 14, pp. 1973-1976
2001
2000
-
Dolor abdominal y diarrea en un varón de 33 años
Medicina Clinica, Vol. 115, Núm. 7, pp. 271-277